Equity Research Drug Manufacturers - Specialty & Generic

Should You Buy Raphael Pharmaceutical Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Raphael Pharmaceutical Inc. (RAPH) presents a moderate quality profile with a QOC score of 4.6/10. Trading at $1.40, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.

The short answer: 0 of 0 CirclFi valuation models project upside for Raphael Pharmaceutical Inc. (RAPH) at $1.40 — the models are evenly split, with a Quality Score of 4.6/10 and Value-Trap risk of 31/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 4.6/10 — Weak — below-average fundamentals
  • Value Trap Risk: 31/100 — Low — manageable risk
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

4.6 /10

Weak — below-average fundamentals

Value Trap Risk

31 /100
Low

Low — manageable risk

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for Raphael Pharmaceutical Inc. (RAPH) in 2026?

What Is the Bull Case vs the Bear Case for Raphael Pharmaceutical Inc. (RAPH)?

Bull case versus bear case for Raphael Pharmaceutical Inc. (RAPH) at $1.40, derived from 0 active CirclFi valuation models on 2026-08-27.
Bull case Bear case
No active model projects meaningful upside for RAPH at $1.40. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for RAPH. The Value Trap score of 31/100 still argues for some caution.

How Does RAPH Compare to Its Drug Manufacturers - Specialty & Generic Peers?

CPMD CannaPharmaRX, Inc.
4.6
CPHI China Pharma Holding
4.6
PNXP Pineapple Express Ca
4.7
BSPK Bespoke Extracts, In
4.5
PRFX PRF Technologies Ltd
4.7
CTOR Citius Oncology, Inc
4.4
ANIP ANI Pharmaceuticals,
9.0
BHC Bausch Health Compan
6.8

Valuation data pages: CPMD · CPHI · PNXP · BSPK · PRFX · CTOR · ANIP · BHC · LFCR · UTHR · AMPH

See full Drug Manufacturers - Specialty & Generic rankings →

Which Other Stocks Score Like RAPH on Quality?

Closest companies to RAPH’s Quality of Company score of 4.6/10, across all industries.

Which Drug Manufacturers - Specialty & Generic Screens Does RAPH Appear In?

Why Do CirclFi’s 0 Models Disagree on RAPH?

What Are the Biggest Risks of Buying RAPH Stock?

Weak Fundamentals

QOC 4.6/10 signals below-average quality.

Macro/Sector Risk

Drug Manufacturers - Specialty & Generic headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View RAPH Data Page →

So Is Raphael Pharmaceutical Inc. (RAPH) Worth Buying in 2026?

Raphael Pharmaceutical Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. Raphael Pharmaceutical Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About RAPH Stock?

Should I buy RAPH stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for RAPH at $1.40. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Raphael Pharmaceutical Inc.?

Key risks include: a below-average Quality Score of 4.6/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.

How does RAPH compare to its competitors?

Among Drug Manufacturers - Specialty & Generic peers, RAPH holds a Quality Score of 4.6/10. Comparable companies include CPMD (QOC 4.6), CPHI (QOC 4.6), PNXP (QOC 4.7). The relative ranking helps investors identify whether RAPH offers better fundamental quality than alternatives in the same sector.

Is RAPH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RAPH's Quality Score of 4.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy RAPH at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for RAPH.

View RAPH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →